24 October 2018
Vol 10, Issue 464

About The Cover

Cover image expansion

ONLINE COVER Outfoxing Medulloblastoma. In addition to carrying a poor prognosis, medulloblastoma groups 3 and 4 are heterogeneous tumors that are difficult to target. Shown here is a species of Digitalis or foxglove, the source of the approved drug digoxin that is used to treat cardiac dysfunction. Huang et al. used systems biology to repurpose drugs for potential use against groups 3 and 4 medulloblastoma. Digoxin prolonged survival, both alone and in combination with radiation, in orthotopic patient-derived xenograft mouse models. Importantly, it did so at concentrations that could be tolerated in humans, indicating that digoxin could be a promising therapeutic avenue for treating these deadly brain tumors. [CREDIT: JEANNE WHITE/SCIENCE SOURCE]